Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on June 19, 2018, covering events occurring on June 18, 2018. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific contractual amendment regarding real estate.
Material Changes
On June 18, 2018, the Company entered into a First Amendment to its License Agreement with MIL 21E, LLC regarding the lease of approximately 19,833 rentable square feet at 21 Erie Street, Cambridge, Massachusetts. The material changes include:
- Commencement Date: Delayed to May 15, 2018.
- Rental Rate Reduction: The monthly rental rate for the last 18 months of the License Term was reduced from $388,396 to $330,550.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed beyond the terms of the lease amendment. There are no unusual items reported in this filing.
Key Facts for Investor Verification
- Verify the total cost savings resulting from the reduced monthly rental rate over the remaining 18-month term.
- Confirm the impact of the delayed commencement date on the Company's operational timeline.
- Review the full text of the First Amendment to License Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.